GlassScriptPhysician profile
John L Gosserand
NPI 1356371231
$14,717.41
in general payments reported to CMS, 2019-2025
36 companies · $2,644 in 2025
The $2,644 reported for 2025 was more than what a typical Hepatology provider received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,886 · 2020: $1,434 · 2021: $1,987 · 2022: $2,147 · 2023: $2,179 · 2024: $2,439 · 2025: $2,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,170 · Education: $93.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,169.77 |
| Education | $93.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,307.54 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $3,298.57 | 2019-2025 | |
| Janssen Biotech, INC. | $1,544.56 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $1,230.74 | 2019-2025 | Entyvio, Gattex |
| Qol Medical, LLC | $729.15 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $609.05 | 2021-2024 | Zeposia |
| Pfizer INC. | $443.32 | 2019-2025 | |
| Ardelyx, INC. | $422.59 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $312.81 | 2019-2025 | Sutab, Suflave |
| Gilead Sciences, INC. | $307.88 | 2019-2025 | Livdelzi |
| Intercept Pharmaceuticals, INC. | $277.09 | 2020-2025 | Ocaliva |
| Allergan, INC. | $243.33 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $225.70 | 2019-2023 | Linzess |
| Nestle Healthcare Nutrition INC. | $204.23 | 2020-2023 | |
| Redhill Biopharma INC. | $198.02 | 2021-2023 | Talicia, Movantik, Aemcolo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $184.40 | 2021-2024 | Dificid |
| Lilly USA, LLC | $183.32 | 2023-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $142.08 | 2019-2023 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $138.67 | 2024-2025 | Iqirvo, Bylvay |
| Phathom Pharmaceuticals, INC. | $114.95 | 2024-2025 | Voquezna |
| Genzyme Corporation | $111.83 | 2023-2025 | |
| Madrigal Pharmaceuticals | $89.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Evoke Pharma, INC. | $79.46 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $67.62 | 2024-2025 | Zenpep |
| Pentax of America, INC. | $48.62 | 2025 | Pentax Medical, Inspira, C2 Cryoballoon Focal Controller |
| Ucb, INC. | $29.81 | 2019 | |
| Amgen INC. | $25.44 | 2023 | Avsola |
| Boston Scientific Corporation | $24.91 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.29 | 2023 | Cyltezo |
| Organon LLC | $18.79 | 2024 | |
| Sandoz INC. | $15.83 | 2023 | Hyrimoz |
| Capsovision, INC. | $14.51 | 2023 | Capsocam Plus |
| Mylan Institutional INC. | $14.08 | 2023 | |
| Echosens North America, INC. | $13.12 | 2021 | |
| Alfasigma USA, INC. | $13.12 | 2020 | |
| Shire North American Group INC | $13.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gosserand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.